Nationwide shortage of tuberculin skin test antigens : CDC recommendations for patient care and public health practice

Details

• Corporate Authors:
  Centers for Disease Control and Prevention (U.S.)
• Description:
  April 12, 2013, 11:00 EDT
  
  CDC HAN-00345
  
  TUBERSOL®, a product of Sanofi Pasteur Limited, is in shortage nationwide until at least the end of May 2013. TUBERSOL® is one of two purified-protein derivative (PPD) tuberculin products that are licensed by the United States Food and Drug Administration (FDA). The manufacturer notified CDC that 50-dose vials of TUBERSOL® are unavailable and that the supplies of 10-dose vials will be limited. This notice advises public health officials, clinicians, and workers in occupational health and infection control about how to adapt to the shortage.
  
  JHP Pharmaceuticals, LLC, the manufacturer of APLISOL®, the other PPD tuberculin product that is licensed by FDA, has notified FDA that the product is on allocation and is available in restricted quantity. Acute local shortages of APLISOL® are being reported to CDC by healthcare providers who switch from TUBERSOL® to APLISOL®.
  
  
• Subjects:
  Health Services Needs And Demand Public Health Practice Tuberculin/diagnostic Use Tuberculin Test/methods Tuberculosis/diagnosis
• Source:
  HAN ; 345
• Series:
  Health Alert Network
• Document Type:
  HAN Info Service
• Place as Subject:
  United States
• Pages in Document:
  2 unnumbered pages
• Issue:
  345
• Collection(s):
  Health Alert Network (HAN)
• Main Document Checksum:
  urn:sha-512:97e598d276a0150d4b9353736d9e74fc9d6dbe2f6796660e0eeaa0f47b11871a3059ee1933e8eb18b52603bfea4006e060170cab1222aaae1d1c5323e439244b
• Download URL:
  https://stacks.cdc.gov/view/cdc/25254/cdc_25254_DS1.pdf
• File Type:
  [PDF - 1.34 MB ]